Dextromethorphan/bupropion

Last updated

Dextromethorphan/bupropion
Dextromethorphan.svg
Dextromethorphan
Bupropion.svg
Bupropion
Combination of
Dextromethorphan NMDA receptor antagonist, σ1 receptor agonist, serotonin-norepinephrine reuptake inhibitor, nicotinic acetylcholine receptor negative allosteric modulator, and other actions
Bupropion Norepinephrine–dopamine reuptake inhibitor and nicotinic acetylcholine receptor negative allosteric modulator
Clinical data
Trade names Auvelity
Other namesDXM/BUP; AXS-05
License data
Routes of
administration 		By mouth
ATC code
Legal status
Legal status
Identifiers
CAS Number
KEGG

Dextromethorphan/bupropion (DXM/BUP), sold under the brand name Auvelity, is a combination medication for the treatment of major depressive disorder (MDD). [1] Its active components are dextromethorphan (DXM) and bupropion. [1] Patients who stayed on the medication had an average of 11% greater reduction in depressive symptoms than placebo in an FDA approval trial. [2] [3] It is taken as a tablet by mouth. [1]

Contents

Side effects of dextromethorphan/bupropion include dizziness, headache, diarrhea, somnolence, dry mouth, sexual dysfunction, and hyperhidrosis, among others. [1] The mechanism of action of dextromethorphan/bupropion in the treatment of depression is unknown. [1]

Dextromethorphan/bupropion was developed by Axsome Therapeutics and was approved for the treatment of major depressive disorder in the United States in August 2022. [1]

Medical uses

Depression

Antidepressant efficacy of dextromethorphan/bupropion (Auvelity) versus placebo in the GEMINI clinical trial. The scores shown are the mean total depression scores on the MADRS over 6 weeks. Only 124/156 patients completed 6 weeks of Auvelity while 150/162 patients completed 6 weeks of placebo, consistent with a high rate of adverse reactions. Antidepressant efficacy of dextromethorphan and bupropion (Auvelity) versus placebo in the GEMINI trial.png
Antidepressant efficacy of dextromethorphan/bupropion (Auvelity) versus placebo in the GEMINI clinical trial. The scores shown are the mean total depression scores on the MADRS over 6 weeks. Only 124/156 patients completed 6 weeks of Auvelity while 150/162 patients completed 6 weeks of placebo, consistent with a high rate of adverse reactions.

Dextromethorphan/bupropion is approved for the treatment of major depressive disorder. [1] Dextromethorphan and bupropion have both individually been reported to be effective for the treatment of this condition. [6] [7] [8] The effect size of bupropion alone relative to placebo for depression is small, [7] [8] whereas only limited evidence exists for dextromethorphan alone. [6] The combination was approved in the US on the basis of two regulatory clinical trials. [1]

In Study 1 (GEMINI), a 6-week randomized controlled trial of dextromethorphan/bupropion versus placebo in people with major depressive disorder, scores on the Montgomery–Åsberg Depression Rating Scale (MADRS)—a scale with a range of 0 to 60 points—decreased with dextromethorphan/bupropion by 15.9 points from a baseline score of 33.6 points (an approximate 47% reduction) and decreased with placebo by 12.1 points from a baseline score of 33.2 points (an approximate 36% reduction). [1] [3] This resulted in a least-squares mean difference in reduction of depression scores between dextromethorphan/bupropion and placebo of 3.9 points, with the placebo group showing approximately 76% of the improvement in depression scores as the dextromethorphan/bupropion group and with depression scores at baseline improving overall about 11% more with the medication than with placebo. [1] [3] In antidepressant trials of 6 to 8 weeks duration recorded in the Food and Drug Administration (FDA) database, the average difference from placebo with other antidepressants was 2.5 points. [3] The mean improvement in scores with dextromethorphan/bupropion was statistically significant but not clinically significant [9] relative to placebo at all assessed timepoints including at the end of week 1, although at the end of the study some patients did have clinically significant improvement. [1] [3]

In Study 2 (STRIDE-1), dextromethorphan/bupropion was compared with bupropion alone in another randomized controlled trial. [1] The dose of bupropion in the study was lower than the target dose recommended for clinical practice. [10] In this study, dextromethorphan/bupropion showed significantly greater improvement than bupropion alone in the first two weeks of treatment but not by week 6 of treatment in people with major depressive disorder. [1] [11] The baseline scores were 33.4 points with dextromethorphan/placebo and 33.2 points with placebo, while the score reductions at week 1 were 5.2 points on the MADRS with dextromethorphan/bupropion and 3.6 points with bupropion (a 1.6-point difference), at week 2 were 8.0 points with dextromethorphan/bupropion and 6.1 points with bupropion (a 1.9-point difference), and at week 6 were 11.6 points with dextromethorphan/bupropion and 9.4 points with bupropion (a 2.2-point difference). [11] [12] On the basis of this trial, the FDA concluded that dextromethorphan contributes to the apparent antidepressant effects of dextromethorphan/bupropion. [1]

Side effects

Side effects of dextromethorphan/bupropion include dizziness, nausea, headache, diarrhea, somnolence, dry mouth, sexual dysfunction (including abnormal orgasm, erectile dysfunction, decreased libido, and anorgasmia), hyperhidrosis, anxiety, constipation, decreased appetite, insomnia, arthralgia, fatigue, paresthesia, and blurred vision. [1] These side effects occurred at rates ≥2% and to a greater extent than with placebo in clinical trials. [1]

Pharmacology

Pharmacodynamics

Dextromethorphan acts as an NMDA receptor antagonist, σ1 receptor agonist, and serotonin–norepinephrine reuptake inhibitor, among other actions, while bupropion acts as a norepinephrine–dopamine reuptake inhibitor and nicotinic acetylcholine receptor negative allosteric modulator. [1] [13] Bupropion is also a potent inhibitor of CYP2D6, and thereby inhibits the metabolism of dextromethorphan. [13] Dextromethorphan/bupropion has less activity as an NMDA receptor antagonist than dextromethorphan alone. [11] This is because bupropion is a potent CYP2D6 inhibitor and prevents the bioactivation of dextromethorphan into dextrorphan, a much more potent NMDA receptor antagonist and weaker serotonin reuptake inhibitor than dextromethorphan itself. [11] The mechanism of action of dextromethorphan/bupropion in the treatment of depression is unknown, although the preceding pharmacological actions are assumed to be involved.

Pharmacokinetics

When administered together as dextromethorphan/bupropion, the elimination half-life of dextromethorphan is 22 hours and the elimination half-life of bupropion is 15 hours. [1] The elimination half-lives of bupropion active metabolites are 35 hours for hydroxybupropion, 44 hours for erythrohydrobupropion, and 33 hours for threohydrobupropion. [1] Bupropion inhibits the metabolism of dextromethorphan by inhibiting the enzyme CYP2D6, the major enzyme responsible for the metabolism of dextromethorphan. [1] This in turn improves the bioavailability of dextromethorphan, prolongs its half-life, prevents its metabolism into dextrorphan, and increases the ratio of dextromethorphan to dextrorphan in the body. [1] [13] [14] [6] [15]

History

Dextromethorphan/bupropion was developed by Axsome Therapeutics. [16] It was approved for the treatment of major depressive disorder by the US Food and Drug Administration in August 2022. [1]

Society and culture

Brand names

Dextromethorphan/bupropion is sold under the brand name Auvelity. [1]

Dextromethorphan/bupropion is not a controlled substance in the United States. [1] The misuse potential of dextromethorphan and bupropion has not been systematically studied. [1] However, both dextromethorphan and bupropion may have misuse liability at supratherapeutic doses. [1] [17] [18] [19] Despite the known misuse potential of dextromethorphan, it is available widely as an over-the-counter drug. [18] Conversely, bupropion is a prescription-only medication. [20]

Research

Dextromethorphan/bupropion is under development for the treatment of agitation in Alzheimer's disease and smoking withdrawal. [16] [21] [22] As of August 2022, it is in phase III clinical trials for agitation and phase II trials for smoking withdrawal. [16]

Related Research Articles

<span class="mw-page-title-main">Antidepressant</span> Class of medication used to treat depression and other conditions

Antidepressants are a class of medications used to treat major depressive disorder, anxiety disorders, chronic pain, and addiction.

<span class="mw-page-title-main">Tricyclic antidepressant</span> Class of medications

Tricyclic antidepressants (TCAs) are a class of medications that are used primarily as antidepressants. TCAs were discovered in the early 1950s and were marketed later in the decade. They are named after their chemical structure, which contains three rings of atoms. Tetracyclic antidepressants (TeCAs), which contain four rings of atoms, are a closely related group of antidepressant compounds.

<span class="mw-page-title-main">Sertraline</span> Antidepressant (SSRI class) medication

Sertraline, sold under the brand name Zoloft among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. The effectiveness of sertraline for depression is similar to that of other antidepressants, and the differences are mostly confined to side effects. Sertraline is better tolerated than the older tricyclic antidepressants. Sertraline is effective for panic disorder, social anxiety disorder, generalized anxiety disorder (GAD), and obsessive–compulsive disorder (OCD). Although approved for post-traumatic stress disorder (PTSD), sertraline leads to only modest improvement in this condition. Sertraline also alleviates the symptoms of premenstrual dysphoric disorder (PMDD) and can be used in sub-therapeutic doses or intermittently for its treatment.

<span class="mw-page-title-main">Bupropion</span> Medication mainly used for depression and smoking cessation

Bupropion, formerly called amfebutamone, and sold under the brand name Wellbutrin among others, is an atypical antidepressant primarily used to treat major depressive disorder and to support smoking cessation. It is also popular as an add-on medication in the cases of "incomplete response" to the first-line selective serotonin reuptake inhibitor (SSRI) antidepressant. Bupropion has several features that distinguish it from other antidepressants: it does not usually cause sexual dysfunction, it is not associated with weight gain and sleepiness, and it is more effective than SSRIs at improving symptoms of hypersomnia and fatigue. Bupropion, particularly the immediate release formulation, carries a higher risk of seizure than many other antidepressants, hence caution is recommended in patients with a history of seizure disorder. The medication is taken by mouth.

<span class="mw-page-title-main">Venlafaxine</span> Antidepressant medication

Venlafaxine, sold under the brand name Effexor among others, is an antidepressant medication of the serotonin–norepinephrine reuptake inhibitor (SNRI) class. It is used to treat major depressive disorder, generalized anxiety disorder, panic disorder, and social anxiety disorder. Studies have shown that venlafaxine improves post-traumatic stress disorder (PTSD). It may also be used for chronic neuropathic pain. It is taken orally. It is also available as the salt venlafaxine besylate in an extended-release formulation.

<span class="mw-page-title-main">Norepinephrine reuptake inhibitor</span> Class of drug

A norepinephrine reuptake inhibitor or noradrenaline reuptake inhibitor or adrenergic reuptake inhibitor (ARI), is a type of drug that acts as a reuptake inhibitor for the neurotransmitters norepinephrine (noradrenaline) and epinephrine (adrenaline) by blocking the action of the norepinephrine transporter (NET). This in turn leads to increased extracellular concentrations of norepinephrine and epinephrine and therefore can increase adrenergic neurotransmission.

<span class="mw-page-title-main">Dextrorphan</span> Psychoactive cough suppressant medication

Dextrorphan (DXO) is a psychoactive drug of the morphinan class which acts as an antitussive or cough suppressant and in high doses a dissociative hallucinogen. It is the dextrorotatory enantiomer of racemorphan; the levorotatory enantiomer is levorphanol. Dextrorphan is produced by O-demethylation of dextromethorphan by CYP2D6. Dextrorphan is an NMDA antagonist and contributes to the psychoactive effects of dextromethorphan.

<span class="mw-page-title-main">Dextromethorphan</span> Cough suppressant, antidepressant, and dissociative drug

Dextromethorphan (DXM), sold under the trade name Robitussin among others, is a cough suppressant used in many cough and cold medicines. In 2022, the FDA approved the combination dextromethorphan/bupropion to serve as a rapid acting antidepressant in patients with major depressive disorder.

<span class="mw-page-title-main">Trazodone</span> Antidepressant medication

Trazodone, sold under many brand names, is an antidepressant medication, used to treat major depressive disorder, anxiety disorders, and insomnia. It is a phenylpiperazine compound of the serotonin antagonist and reuptake inhibitor (SARI) class. The medication is taken orally.

<span class="mw-page-title-main">Agomelatine</span> Atypical antidepressant classified primarily as a melatonin receptor agonist

Agomelatine, sold under the brand names Valdoxan and Thymanax, among others, is an atypical antidepressant most commonly used to treat major depressive disorder and generalized anxiety disorder. One review found that it is as effective as other antidepressants with similar discontinuation rates overall but fewer discontinuations due to side effects. Another review also found it was similarly effective to many other antidepressants.

<span class="mw-page-title-main">Gepirone</span> Medication used for major depressive disorder

Gepirone, sold under the brand name Exxua, is a medication used for the treatment of major depressive disorder. It is taken orally.

<span class="mw-page-title-main">Esketamine</span> Medication

Esketamine, sold under the brand names Spravato and Ketanest among others, is the S(+) enantiomer of ketamine. It is a dissociative hallucinogen drug used as a general anesthetic and as an antidepressant for treatment of depression. Esketamine is the active enantiomer of ketamine in terms of NMDA receptor antagonism and is more potent than racemic ketamine.

<span class="mw-page-title-main">Vilazodone</span> Antidepressant medication

Vilazodone, sold under the brand name Viibryd among others, is a medication used to treat major depressive disorder. It is classified as a serotonin modulator and is taken by mouth.

<span class="mw-page-title-main">Levomilnacipran</span> SNRI antidepressant drug

Levomilnacipran is an antidepressant which was approved in the United States in 2013 for the treatment of major depressive disorder (MDD) in adults. It is the levorotatory enantiomer of milnacipran, and has similar effects and pharmacology, acting as a serotonin–norepinephrine reuptake inhibitor (SNRI).

Dextromethorphan/quinidine, sold under the brand name Nuedexta, is a fixed-dose combination medication for the treatment of pseudobulbar affect (PBA). It contains dextromethorphan (DXM) and the class I antiarrhythmic agent quinidine.

<span class="mw-page-title-main">Rislenemdaz</span> Investigational antidepressant compound

Rislenemdaz is an orally active, selective NMDA receptor subunit 2B (NR2B) antagonist which is under development by Cerecor in the United States as an adjunctive therapy for treatment-resistant depression (TRD). In November 2013, phase II clinical trials were initiated, and in the same month, rislenemdaz received Fast Track Designation from the Food and Drug Administration for TRD.

<span class="mw-page-title-main">4-Chlorokynurenine</span> Investigational antidepressant compound

L-4-Chlorokynurenine is an orally active small molecule prodrug of 7-chlorokynurenic acid, a NMDA receptor antagonist. It was investigated as a potential rapid-acting antidepressant.

Deudextromethorphan/quinidine is a combination of deudextromethorphan and quinidine (Q) which is under development by Avanir Pharmaceuticals for the treatment of a variety of neurological and psychiatric indications. The pharmacological profile of d-DXM/Q is similar to that of dextromethorphan/quinidine (DXM/Q). DXM and d-DXM act as σ1 receptor agonists, NMDA receptor antagonists, and serotonin–norepinephrine reuptake inhibitors, among other actions, while quinidine is an antiarrhythmic agent acting as a CYP2D6 inhibitor. Quinidine inhibits the metabolism of DXM and d-DXM into dextrorphan (DXO), which has a different pharmacological profile from DXM. Deuteration of DXM hinders its metabolism by CYP2D6 into DXO, thereby allowing for lower doses of quinidine in the combination. This in turn allows for lower potential for drug interactions and cardiac adverse effects caused by quinidine. As of September 2020, d-DXM/Q is in phase 3 clinical trials for agitation, phase 2/3 trials for schizophrenia, and phase 2 trials for brain injuries, impulse control disorders, major depressive disorder, and neurodegenerative disorders.

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 "Auvelity- dextromethorphan hydrobromide, bupropion hydrochloride tablet, multilayer, extended release". DailyMed. 15 December 2022. Retrieved 21 January 2023.
  2. 1 2 "AUVELITY (dextromethorphan hydrobromide and bupropion hydrochloride) extended-release tablets, for oral use" (PDF). October 2022.
  3. 1 2 3 4 5 6 Iosifescu DV, Jones A, O'Gorman C, Streicher C, Feliz S, Fava M, et al. (May 2022). "Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI)". J Clin Psychiatry. 83 (4). doi: 10.4088/JCP.21m14345 . PMID   35649167. S2CID   249104681.
  4. 1 2 O'Gorman C, Jones A, Thomas Z, Iosifescu DV, Tabuteau H (June 2021). "W19 Rapid Effects of AXS-05, an Oral NMDA Receptor Antagonist, in Major Depressive Disorder: Results from Two Randomized, Double-Blind, Controlled Trials" (PDF). American Society of Clinical Psychopharmacology, Annual Meeting 2021, 1-4 June 2021 (PDF).
  5. 1 2 O'Gorman C, Feliz S, Jones A, Streicher C, Thomas Z, Tabuteau H (June 2021). "W20 Effects of AXS-05, an Oral NMDA Receptor Antagonist with Multimodal Activity, on Patient Reported Depressive Symptoms in Major Depressive Disorder: Results from the GEMINI Phase 3 Double-Blind, Placebo-Controlled Trial" (PDF) (PDF).
  6. 1 2 3 Majeed A, Xiong J, Teopiz KM, Ng J, Ho R, Rosenblat JD, et al. (March 2021). "Efficacy of dextromethorphan for the treatment of depression: a systematic review of preclinical and clinical trials". Expert Opin Emerg Drugs. 26 (1): 63–74. doi:10.1080/14728214.2021.1898588. ISSN   1472-8214. PMID   33682569. S2CID   232141396.
  7. 1 2 Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JP, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JP, Geddes JR (April 2018). "Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis". Lancet. 391 (10128): 1357–1366. doi:10.1016/S0140-6736(17)32802-7. PMC   5889788 . PMID   29477251.
  8. 1 2 Monden R, Roest AM, van Ravenzwaaij D, Wagenmakers EJ, Morey R, Wardenaar KJ, de Jonge P (August 2018). "The comparative evidence basis for the efficacy of second-generation antidepressants in the treatment of depression in the US: A Bayesian meta-analysis of Food and Drug Administration reviews" (PDF). J Affect Disord. 235: 393–398. doi:10.1016/j.jad.2018.04.040. PMID   29677603. S2CID   5011570.
  9. ↑ Turkoz I, Alphs L, Singh J, Jamieson C, Daly E, Shawi M, Sheehan J, Trivedi M, Rush A (2021). "Clinically meaningful changes on depressive symptom measures and patient-reported outcomes in patients with treatment-resistant depression". Acta Psychiatrica Scandinavica. 143 (3): 253–263. doi:10.1111/acps.13260. PMC   7986932 . PMID   33249552.
  10. ↑ Fava M, Rush A, Thase M, Clayton A, Stahl S, Pradko J, Johnston J (2005). "15 Years of Clinical Experience With Bupropion HCl: From Bupropion to Bupropion SR to Bupropion XL". The Primary Care Companion to the Journal of Clinical Psychiatry. 7 (3): 106–113. doi:10.4088/pcc.v07n0305. PMC   1163271 . PMID   16027765.
  11. 1 2 3 4 Sakurai H, Yonezawa K, Tani H, Mimura M, Bauer M, Uchida H (July 2022). "Novel Antidepressants in the Pipeline (Phase II and III): A Systematic Review of the US Clinical Trials Registry". Pharmacopsychiatry. 55 (4): 193–202. doi:10.1055/a-1714-9097. PMC   9259184 . PMID   35045580.
  12. ↑ Axsome Therapeutics (30 March 2020). "STRIDE-1 Phase 3 Trial of AXS-05 in TRD Topline Results Conference Call" (PDF).
  13. 1 2 3 Jefferson JW, Pradko JF, Muir KT (November 2005). "Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations". Clin Ther. 27 (11): 1685–95. doi:10.1016/j.clinthera.2005.11.011. PMID   16368442.
  14. ↑ Stahl SM (October 2019). "Dextromethorphan/Bupropion: A Novel Oral NMDA (N-methyl-d-aspartate) Receptor Antagonist with Multimodal Activity". CNS Spectr. 24 (5): 461–466. doi: 10.1017/S1092852919001470 . PMID   31566163. S2CID   203607617.
  15. ↑ Schoedel KA, Morrow SA, Sellers EM (2014). "Evaluating the safety and efficacy of dextromethorphan/quinidine in the treatment of pseudobulbar affect". Neuropsychiatr Dis Treat. 10: 1161–74. doi: 10.2147/NDT.S30713 . PMC   4079824 . PMID   25061302.
  16. 1 2 3 "Bupropion/dextromethorphan". Adis Insight. Archived from the original on 21 September 2021. Retrieved 16 December 2019.
  17. ↑ Silva AR, Dinis-Oliveira RJ (May 2020). "Pharmacokinetics and pharmacodynamics of dextromethorphan: clinical and forensic aspects". Drug Metab Rev. 52 (2): 258–282. doi:10.1080/03602532.2020.1758712. PMID   32393072. S2CID   218599441.
  18. 1 2 Stanciu CN, Penders TM, Rouse EM (August 2016). "Recreational use of dextromethorphan, "Robotripping"-A brief review". Am J Addict. 25 (5): 374–7. doi:10.1111/ajad.12389. PMID   27288091.
  19. ↑ Costa R, Oliveira NG, Dinis-Oliveira RJ (August 2019). "Pharmacokinetic and pharmacodynamic of bupropion: integrative overview of relevant clinical and forensic aspects". Drug Metab Rev. 51 (3): 293–313. doi:10.1080/03602532.2019.1620763. PMID   31124380. S2CID   163167323.
  20. ↑ "Bupropion: Drug Uses, Dosage, Side Effects".
  21. ↑ Wilkinson ST, Sanacora G (February 2019). "A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems". Drug Discovery Today. 24 (2): 606–615. doi:10.1016/j.drudis.2018.11.007. PMC   6397075 . PMID   30447328.
  22. ↑ "Axsome depression drug meets late-stage study goal, shares soar 56%". Reuters. 16 December 2019. Archived from the original on 16 December 2019. Retrieved 16 December 2019.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.